2000
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
Murren J, Peccerillo K, DiStasio S, Li X, Leffert J, Pizzorno G, Burtness B, McKeon A, Cheng Y. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemotherapy And Pharmacology 2000, 46: 43-50. PMID: 10912577, DOI: 10.1007/s002800000115.Peer-Reviewed Original ResearchConceptsDose of irinotecanElimination of irinotecanDrug AdministrationAdvanced cancerFirst cycle patientsChemotherapy-related toxicityDose of paclitaxelClinical side effectsSequence of administrationBlood cell elementsNonhematologic toxicityReversible neutropeniaFirst doseMost patientsPartial responseCycle patientsDose escalationMild diarrheaPreclinical dataPlasma concentrationsSide effectsIrinotecanPatientsPharmacokinetic parametersWeekly schedule
1999
A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
Burtness B, Psyrri A, Rose M, D’Andrea E, Staugaard-Hahn C, Henderson-Bakas M, Clark M, Mechanic S, Krause D, Snyder E, Cooper R, Abrantes J, Corringham R, Deisseroth A, Cooper D. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplantation 1999, 23: 311-315. PMID: 10100573, DOI: 10.1038/sj.bmt.1701589.Peer-Reviewed Original ResearchConceptsSchedule of paclitaxelDose escalationH infusionPeripheral blood progenitor cellsDose of paclitaxelPhase I trialBlood progenitor cellsStem cell yieldStem cellsTolerable toxicityI trialInfusion scheduleDose levelsPhase IPaclitaxelDoseProgenitor cellsCells/NeuropathyFilgrastimInfusionEscalation